Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-27T01:59:55.488Z Has data issue: false hasContentIssue false
  • English
  • Français

Acute and continuation pharmacological treatment of children and adolescents with bipolar disorders; a summary of two previous studies

Published online by Cambridge University Press:  18 September 2015

R.A. Kowatch ,
Th.J. Carmody ,
T. Suppes ,
J.H. Hume ,
M. Kromelis ,
G.J. Emslie  and
W.A. Weinberg
R.A. Kowatch*
Affiliation:
The University of Texas Southwestern. Dallas, U.S.A
T. Suppes
Affiliation:
Medical Center, Dallas, U.S.A
J.H. Hume
Affiliation:
Medical Center, Dallas, U.S.A
M. Kromelis
Affiliation:
Medical Center, Dallas, U.S.A
G.J. Emslie
Affiliation:
Childrens Medical Center, Dallas, U.S.ADepartments of Psychiatry
W.A. Weinberg
Affiliation:
Childrens Medical Center, Dallas, U.S.ADepartments of Psychiatry
*
The University of Texas, Southwestern Medical Center at Dallas, Department of Psychiatry, 5323 Harry Hines Blvd, Dallas, TX 75390-9070, United StatesTel 214-648-4978, Fax 214-648-4979, E-mail [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

We report the results of an acute-phase and continuation-phase study of the pharmacological treatment of children and adolescents with bipolar disorders. The acute phase study, with a duration of 6-8 weeks, aimed at developing effect sizes (ES) for lithium, divalproex sodium, and carbamazepine, in the acute phase treatment of Bipolar I or II children and adolescents during a mixed or manic episode. During the acute-phase of treatment, 42 outpatients with a mean age of 11.4 yr. (20 with Bipolar I Disorder and 22 with Bipolar II Disorder) were randomly assigned to 6-8 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly CGI Improvement scores and the Young Mania Rating Scale. Using a ≥ 50% change from baseline to exit in the Y-MRS scores to define response, the effect size for divalproex sodium was 1.63,1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were: sodium divalproex 53%; lithium 38%; and carbamazepine 38% (x 2=0.85, 2 d.f., p=0.60). Thirty-five subjects continued in open, treatment for another 16-18 weeks, for a total of 24 weeks of prospective treatment. Overall, of the thirty-five continuation phase subjects, thirty (85%) were categorized as responders at the end of the continuation phase of treatment. Of these thirty-five subjects, 13 (37%) were only on a single mood stabilizer and no other psychotropic agents at the end of the continuation phase. Thirty-one percent of subjects in continuation were also treated with a stimulant medication in addition to mood stabilizers.

Keywords

bipolar disorderchildrenadolescentslithiumcarbamazepineand divalproex sodium
Type
Research Article
Information
Acta Neuropsychiatrica , Volume 12 , Issue 3 , September 2000 , pp. 145 - 149
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Lewinsohn, PM. Klein, DN. Scolcy, JR. Bipolar disorders in a community sample of older adolescents: prevalence, phenomenology, comorbidity, and course. J Am Acad Child Adolesc Psychiatry 1995;34:454–463.CrossRefGoogle Scholar
2.Akiskal, HS, Downs, J, Jordan, P, Watson, S, Daugherty, D, Pruitt, DB. Affective disorders in referred children and younger siblings of manic-depressives. Mode of onset and prospective course. Arch Gen Psychiatry 1985;42:996–1003.CrossRefGoogle ScholarPubMed
3.Geller, B. Luby, J. Child and adolescent bipolar disorder: a review of the past 10 vears. J Am Acad Child Adolesc Psychiatry 1997;36:1168–1176.CrossRefGoogle Scholar
4.Kafantaris, V. Treatment of bipolar disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995;34:732–741.CrossRefGoogle ScholarPubMed
5.Cohen, LS. Statistical power analysis for the behavioral sciences. Hillsdale. NJ: Lawrence Erlbaum Associates; 1988.Google Scholar
6.Kowatch, RA. Suppes, T. Carmody, TJ. Bucci, JP. Hume, JH. Kromelis, M. et al.Effect Size of Lithium. Divalproex Sodium and Carbamazepine In Children and Adolescents with Bipolar Disorder. J Am Acad Child Adoles Psychiatry 2000;39:713–720.CrossRefGoogle ScholarPubMed
7.Kowatch, RA. Carmody, TJ, Suppes, T. Bucci, JP. Hume, JH. Kromelis, M. et al.A Six Month Pharmacological Treatment Study of Children and Adolescents with Bipolar Disoders. J Am Acad Child Adoles Psychialry 2000:submilted.Google Scholar
8.APA. Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington. DC: American Psychiatric Association: 1994.Google Scholar
9.Young, RC. Biggs, JT. Ziegler, VE. Meyer, DA. A rating scale for mania: rcliabilitv. validity and sensitivity. Br J Psychiatry 1978;133:429–35.CrossRefGoogle ScholarPubMed
10.Kaufman, J. Birmaher, B. Brent, D. Rao, U, Flynn, C, Moreci, P. el al.Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997;36:980–988.CrossRefGoogle ScholarPubMed
11.Shaffer, D, Gould, MS. Brasic, J. Ambrosini, P. Fisher, P, Bird, H. et al.A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983;40:1228–1231.CrossRefGoogle ScholarPubMed
12.Spearing, MK. Post, RM, Leverich, GS, Brandt, D, Nolen, W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997;73:159–171.CrossRefGoogle Scholar
13.Weller, EB, Weller, RA, Fristad, MA. Lithium dosage guide for prepubertal children: a preliminary report. J Am Acad Child Adolesc Psychiatry 1986;25:92–95.CrossRefGoogle ScholarPubMed
14.Bowden, CL, Brugger, AM, Swann, AC, Calabrcse, JR, Janicak, PG. Petty, F. et al.Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group [published erratum appears in JAMA 1994 Jun 15;271(23):1830] [see comments]. Jama 1994;271:918–924.CrossRefGoogle ScholarPubMed
15.Geller, B. Cooper, TB. Sun, K. Zimerman, MA. Frazier, J. Williams, M, et al.Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. J Am Acad Child Adolese Psychiatry 1998;37:171–178.CrossRefGoogle ScholarPubMed